Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

Misuzu Tanaka, Daisuke Kobayashi, Yuko Murakami, Norio Ozaki, Tatsuyo Suzuki, Nakao Iwata, Koichi Haraguchi, Ichiro Ieiri, Naoko Kinukawa, Masako Hosoi, Hisakazu Ohtani, Yasufumi Sawada, Kazunori Mine

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT3B) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT3B receptor gene may a.ect paroxetine-induced nausea.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalInternational Journal of Neuropsychopharmacology
Issue number2
Publication statusPublished - Mar 2008

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea'. Together they form a unique fingerprint.

Cite this